Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

rareDMS mapping the sequence determinants of protein stability and its contribution to rare genetic diseases

Coordinator
Agencia Estatal Consejo Superior De Investigaciones Cientificas, Spain
Runs
1 February 2027 to 31 January 2032
Status
Running
EU funding
€1.6m
Total cost
€1.6m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101299258

What the project is doing

In the project's own words, from its summary on CORDIS.

Missense variants cause nearly one-third of all human genetic diseases, yet most have unknown functional consequences. Computational predictors can flag pathogenic variants, but they remain blind to mechanism—whether a mutation destabilizes a protein, mislocalizes it, or alters its interactions. Without mechanism, variant interpretation is incomplete and therapeutic opportunities remain hidden. I previously developed deep mutational scanning (DMS) methods to quantify the effects of >500,000 variants on the stability of >500 human protein domains, revealing that ~50% of pathogenic variants destabilize proteins.

Yet this still covers barely 1% of domains and 2% of unique folds in human. Most of the proteome—including most rare disease proteins—remains experimentally unexplored. Here, we will expand this approach to decode how protein stability is encoded in sequence and how its loss contributes to rare genetic diseases. Specifically, we will:1) Chart the landscape of protein fold stability — generating the broadest DMS survey of fold space to date, covering 800 unique folds to uncover the sequence determinants of stability and refine predictive models.2) Expand stability mapping to full-length proteins in human cells — by generating DMS maps across 500 rare disease proteins, we will reveal how mutations in domains, linkers, and disordered regions shape protein abundance in cells, and test the specificity of stabilizer drugs.3) Dissect how the proteostasis network shapes disease variant outcomes —by systematically mapping how chaperones and degradation pathways interact with mutations, we will reveal variants whose effects emerge under proteostasis decline.

These datasets will serve as reference atlases for clinical variant interpretation across rare diseases— defining which are ‘folding diseases’, and which pathogenic variants are destabilizing—and collectively transform our understanding of how protein stability—and its failure—is encoded in the human genome.

Topics

Who is involved

OrganisationCityCountryRole
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI